G92.02 Immune effector cell-associated neurotoxicity syndrome, grade 2

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade 2

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade 2" designation indicates moderate severity, typically involving some impact on activities of daily living but not requiring intensive care.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms in the context of recent immunotherapy administration. Grading follows standardized criteria (e.g., ASTCT consensus) to assess severity. Laboratory tests and imaging may be used to rule out other causes of neurologic symptoms.

Treatment Options

Management focuses on supportive care and symptom control. Mild cases may require observation, while moderate cases often involve corticosteroids and dose adjustments of immunotherapy. Severe cases may need intensive care support. Treatment is tailored to the patient’s clinical status and response.

Prognosis and Follow-Up

Most patients recover with appropriate management, though recovery time varies. Follow-up includes monitoring for symptom resolution and potential recurrence. Long-term neurologic sequelae are rare but possible. Regular assessments are recommended during and after treatment.

Complications

Potential complications include progression to higher grades of neurotoxicity, seizures, or cerebral edema. In severe cases, respiratory failure or other life-threatening events may occur. Early recognition and intervention reduce risks.

Lifestyle & Prevention

No specific preventive measures exist, but maintaining overall health and adhering to treatment protocols may help. Patients should report new or worsening neurologic symptoms promptly. Avoiding other neurotoxic medications when possible may be considered.

When to Seek Professional Help

Seek immediate medical attention for new or worsening neurologic symptoms, such as confusion, difficulty speaking, seizures, or severe headache, especially after immunotherapy. Early evaluation is critical to prevent progression.

Tips for Medical Coders

Code G92.02 is used for immune effector cell-associated neurotoxicity syndrome of moderate severity (grade 2). Documentation should specify the grade and clinical findings to support the diagnosis. Ensure alignment with clinical guidelines for grading and coding specificity.